Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.36 |
| ▸ | CCR3 | P51677 | 3/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL971177 | 0.86 | CCR3 (0.44) | PRKCAMMP12SCN9ACCR3KMO | |
| SCHEMBL12051141 | 0.84 | TEAD1 (0.43) | PRKCAMMP12SCN9ACCR3KMO | |
| SCHEMBL975006 | 0.82 | SCN9A (0.43) | PRKCAMMP12SCN9ACYP3A4CYP2C19 | |
| SCHEMBL972306 | 0.79 | L3MBTL1 (0.44) | PRKCAMMP12SCN9ACYP3A4CYP2C19 | |
| SCHEMBL27587068 | 0.79 | SCN9A (0.43) | PRKCAMMP12SCN9ACYP3A4CYP2C19 | |
| SCHEMBL12596866 | 0.79 | SCN9A (0.43) | PRKCAMMP12SCN9ACYP3A4CYP2C19 | |
| SCHEMBL10063545 | 0.78 | SCN9A (0.42) | PRKCAMMP12SCN9ACYP3A4CYP2C19 | |
| SCHEMBL973251 | 0.78 | SCN9A (0.42) | PRKCAMMP12SCN9ACYP3A4CYP2C19 | |
| SCHEMBL899942 | 0.78 | SCN9A (0.42) | PRKCAMMP12SCN9ACYP3A4CYP2C19 | |
| SCHEMBL12190721 | 0.78 | SCN9A (0.41) | PRKCAMMP12SCN9ACYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103333162-A | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INT | 2013-10-02 | — | — | CN | disclosed |
| CN-103319464-A | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INT | 2013-09-25 | — | — | CN | disclosed |
| CN-103304541-A | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INT | 2013-09-18 | — | — | CN | disclosed |
| EP-2626354-A1 | Viral polymerase inhibitors | Boehringer Ingelheim International GmbH (DE) | 2013-08-14 | — | — | EP | disclosed |
| EP-1718608-B1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2013-07-17 | — | — | EP | disclosed |
| CN-102911161-A | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INT | 2013-02-06 | — | — | CN | disclosed |
| US-8030309-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-04 | — | — | US | disclosed |
| US-7879851-B2 | such as (E)-3-[2-(1-{[2-(5-Bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carbonyl]-amino}-cyclobutyl)-3-methyl-3H-benzoimidazol-5-yl]-acrylic Acid, used for the treatment of hepatitis C virus infections | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-01 | — | — | US | disclosed |
| US-20110015203-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| CN-101648944-A | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INT DE | 2010-02-17 | — | — | CN | disclosed |
| US-7582770-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-01 | — | — | US | disclosed |
| US-20090170859-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-02 | — | — | US | disclosed |
| CN-1922174-A | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2007-02-28 | — | — | CN | disclosed |
| EP-1718608-A1 | VIRAL POLYMERASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2006-11-08 | — | — | EP | disclosed |
| US-20050222236-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-06 | — | — | US | disclosed |
| WO-2005080388-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170859-A1 | Viral Polymerase Inhibitors | POLR2A, POLR1E, RPP30 | PRKCA 2153/4885MMP12 3491/4885SCN9A 390/4885 |
| US-20050222236-A1 | Viral polymerase inhibitors | POLR2A, POLR1E, RPP30 | PRKCA 2153/4885MMP12 3491/4885SCN9A 390/4885 |
| US-20110015203-A1 | Viral Polymerase Inhibitors | POLR2A, POLR1E, RPP30 | PRKCA 2153/4885MMP12 3491/4885SCN9A 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.